Treatment of Hyperuricemia in Patients With Heart Failure

NCT ID: NCT00422318

Last Updated: 2007-01-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-01-31
• Study Completion Date: 2005-12-31

Brief Summary

The study aims to assess (I) the contribution of UA itself to the CHF pathophysiology and (II) to test the effect of lowering UA by uricosuric treatment in CHF.

Detailed Description

Hyperuricemia is often observed in patients with congestive heart failure (CHF). It has been reported that hyperuricemia is related to exercise capacity, inflammation markers and diastolic dysfunction in such patients. In addition, hyperuricemia in CHF relates to both symptomatic status (i.e. morbidity) as well as impaired prognosis (i.e. mortality). Hyperuricemia is likely to play an important role in the pathophysiology of CHF. Up-regulation of xanthine oxidase (XO) activity in CHF has been shown to contribute to higher uric acid (UA) in CHF and the therapeutic concept of XO inhibition has shown beneficial effects in a number of surrogate markers in these patients. The XO inhibition accounts for substantial decrease in oxygen radical load, the latter is discussed as the main benefit of XO inhibition treatment in hyperuricemic patients. However, whether high uric acid itself is important or merely a marker of XO activity (and hence of increased radical accumulation) is currently under discussion. Therefore, this study aims to assess (I) the contribution of UA itself to the CHF pathophysiology and (II) to test the effect of lowering UA by uricosuric treatment in CHF.

Conditions

Heart Failure; Hyperuricemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Benzbromarone (drug)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• chronic heart failure
• hyperuricemia

Exclusion Criteria

• renal dysfunction (Cr > 2.0 mg/dl)
• under treatment with anti-diabetic agents

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tottori University Hospital

OTHER

Sponsor Role: lead

Principal Investigators

Kazuhide Ogino, MD

Role: PRINCIPAL_INVESTIGATOR

Tottori University Hospital

Locations

Tottori University Hospital

Yonago, , Japan

Countries

Japan

References

Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010 Jan;3(1):73-81. doi: 10.1161/CIRCHEARTFAILURE.109.868604. Epub 2009 Nov 20.

Reference Type: DERIVED

PMID: 19933411 (View on PubMed)

Other Identifiers

#345

Identifier Type: -

Identifier Source: org_study_id